Director, Biostatistics Laboratory
Eric Polley, PhD is an Associate Professor in the Department of Public Health Sciences at The University of Chicago where he is the faculty director for the Data Science concentration in the Master of Public Health program. Dr. Polley was previously an Assistant Professor of Biostatistics in the Department of Quantitative Health Sciences at Mayo Clinic (2015-2021) and a mathematical statistician in the Biometric Research Branch at the U.S. National Cancer Institute (2012-2015). Dr. Polley received his PhD in biostatistics from the University of California, Berkeley in 2010. With Mark van der Laan, they developed the Super Learner ensemble prediction methodology. His research area involves the development and evaluation of prediction methods, innovative methods for diagnostic and prognostic prediction, and precision medicine clinical trial design.
National Cancer Institute
MD
Fellow - Computational Biology
2012
University of California, Berkeley
CA
PhD - Biostatistics
2010
Columbia University
NY
MS - Biostatistics
2005
Saint John's University
MN
BA - Mathematics
2003
Pathogenic Variants, Family History, and Cumulative Risk of Breast Cancer in US Women.
Pathogenic Variants, Family History, and Cumulative Risk of Breast Cancer in US Women. JAMA Oncol. 2025 Oct 09.
PMID: 41066089
Comparative effectiveness of GLP-1 receptor agonists on cardiovascular outcomes among adults with type 2 diabetes and moderate cardiovascular risk: emulation of a target trial.
Comparative effectiveness of GLP-1 receptor agonists on cardiovascular outcomes among adults with type 2 diabetes and moderate cardiovascular risk: emulation of a target trial. Diabetes Res Clin Pract. 2025 Sep 20; 112910.
PMID: 40983112
Comparative Risk of Adverse Pancreatic Events with GLP-1 Receptor Agonists, SGLT2 Inhibitors, DPP4 Inhibitors, and Sulfonylureas among Adults with Type 2 Diabetes at Moderate Cardiovascular Disease Risk.
Comparative Risk of Adverse Pancreatic Events with GLP-1 Receptor Agonists, SGLT2 Inhibitors, DPP4 Inhibitors, and Sulfonylureas among Adults with Type 2 Diabetes at Moderate Cardiovascular Disease Risk. Endocr Pract. 2025 Sep 11.
PMID: 40945659
Using telematics data to evaluate safety policies: a case study of Chicago's red-light camera programme.
Using telematics data to evaluate safety policies: a case study of Chicago's red-light camera programme. Inj Prev. 2025 Aug 27.
PMID: 40866294
Development of an alcohol biosensor non-wear algorithm: laboratory-based machine learning and field-based deployment.
Development of an alcohol biosensor non-wear algorithm: laboratory-based machine learning and field-based deployment. Sci Rep. 2025 Aug 25; 15(1):31154.
PMID: 40851098
Risk of Sight-Threatening Diabetic Retinopathy With GLP-1 RA Use in Routine Clinical Practice: Comparative Effectiveness of Semaglutide, Dulaglutide, Liraglutide, and Exenatide.
Risk of Sight-Threatening Diabetic Retinopathy With GLP-1 RA Use in Routine Clinical Practice: Comparative Effectiveness of Semaglutide, Dulaglutide, Liraglutide, and Exenatide. Ophthalmol Retina. 2025 Aug 05.
PMID: 40774571
Heterogeneity of Cardiovascular Effects of Second-Line Glucose-Lowering Therapies in Adults With Type 2 Diabetes Across the Range of Moderate Baseline Cardiovascular Risk.
Heterogeneity of Cardiovascular Effects of Second-Line Glucose-Lowering Therapies in Adults With Type 2 Diabetes Across the Range of Moderate Baseline Cardiovascular Risk. J Am Heart Assoc. 2025 Jul 17; e040217.
PMID: 40673553
Analysis of more than 400,000 women provides case-control evidence for BRCA1 and BRCA2 variant classification.
Analysis of more than 400,000 women provides case-control evidence for BRCA1 and BRCA2 variant classification. Nat Commun. 2025 May 25; 16(1):4852.
PMID: 40413188
Preclinical NCI-MPACT: prospective modeling of the mutation-based NCI-MPACT clinical trial therapeutic strategy in patient-derived xenograft models.
Preclinical NCI-MPACT: prospective modeling of the mutation-based NCI-MPACT clinical trial therapeutic strategy in patient-derived xenograft models. Front Oncol. 2025; 15:1571635.
PMID: 40458731
Breast Cancer Risk Modification in Women with Pathogenic Variants in BRCA1, BRCA2, ATM, CHEK2, and PALB2.
Breast Cancer Risk Modification in Women with Pathogenic Variants in BRCA1, BRCA2, ATM, CHEK2, and PALB2. Cancer Res Commun. 2025 May 01; 5(5):783-791.
PMID: 40298171
NCI Director's award for the development of the NCI-MATCH clinical trial
National Cancer Institute
2015